LETTER : Difficult choices over MS drug
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Sir: Polly Toynbee's article (11 March) gives the impression that Nottingham health authority's decisions relating to the use of beta- interferon are purely motivated by the need to cut costs. The reality is more complex.
We consulted the local MS groups, GPs, consultants, the community health council, the medical advisory committee and the drug company itself. We also took account of the results of the drug over the five-year trials. After giving full consideration to these views, we decided to put extra funding into the local neurological services in the next year. This will enable more effective treatments to be made available to patients.
Your contention that our public consultation meeting was in some way our response to a "row", that it was to explain why patients couldn't have the drug and that it was only as a result that the health authority found "extra money" is inaccurate. The public meeting was planned to take place following the issue of guidance by the Government. No decision had been taken before the meeting and the meeting directly informed our decision. This was always the planned sequence of events.
There will never be sufficient funds to meet all demands. But we shared these facts in public debate to gain the perspectives of the community and support the clinicians who face the hard decision of selecting the most appropriate patients.
Dr Julie Woodin
Chief Executive
Nottingham Health Authority
David Edwards
Chief Executive
Queen's Medical Centre,
University Hospital NHS Trust
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments